Tredaptive pulled from market after safety concerns

摘要

THE marketing authorisation for Tredaptive (nicotinic acid and laropiprant) has been suspended by the European Medicines Agency, following safety concerns. The drug is currenfly being recalled by the Medicines and Healthcare products Regulatory Agency. Tredaptive is used in conjunction with a statin to treat dyslipidaemia. However, its safety came under review by the EMA in December 2012 when initial results from a long-term study suggested it was no more eifective than statins alone and increased the occurrence of nonfatal but serious side effects.